Trial Profile

A Multicenter, Observational Study to Evaluate the Effectiveness of Lenalidomide (Revlimid) in Subjects With Mantle Cell Lymphoma Who Have Relapsed or Progressed After Treatment With Ibrutinib or Are Refractory or Intolerant to Ibrutinib.

Status: Completed

Phase of Trial: Phase IV

Latest Information Update: 01 Feb 2017

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

24 Jan 2017 Status changed to completed.
06 Dec 2016 Status changed from recruiting to active, no longer recruiting,according to the results published at the 58th Annual Meeting and Exposition of the American Society of Hematology.
06 Dec 2016 Results presented at the 58th Annual Meeting and Exposition of the American Society of Hematology.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com